Papers
2
Total Citations
171
H-Index
2
About
Mark Sanders is a pharmaceutical scientist whose research has made significant contributions to the field of drug metabolism and pharmacokinetics, particularly in the development of automated analytical methodologies for early-stage drug discovery. His work centers on leveraging liquid chromatography-mass spectrometry (LC-MS) technologies to streamline the assessment of metabolic stability in drug candidates, a critical factor in determining whether compounds are viable for further pharmaceutical development. Sanders is perhaps best known for his development of automated high-throughput processes for evaluating in vitro metabolic stability using liver microsomes. His 2008 paper detailing an automated LC-MS approach to determine metabolic stability half-life and intrinsic clearance through substrate depletion has become a foundational reference in the field, accumulating 134 citations. This work, alongside his earlier 2007 publication introducing the MetFast assay — a rapid screening tool for cytochrome P450-mediated first-pass metabolism — demonstrates his commitment to translating complex biochemical assessments into efficient, reproducible workflows suitable for high-throughput pharmaceutical profiling. Together, these contributions have meaningfully accelerated how the pharmaceutical industry identifies and prioritizes drug candidates with optimal metabolic properties during early discovery phases.
Research Focus
Key Achievements
Top Papers
- 1
- 2